TITLE

'Lung' Time Coming: Breo Win Caps Theravance, GSK Efforts

AUTHOR(S)
Osborne, Randy
PUB. DATE
May 2013
SOURCE
BioWorld Today;5/13/2013, Vol. 24 Issue 91, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the approval by the U.S. Food and Drug Administration (FDA) for Breo (fluticasone furoate/vilanterol) for long-term treatment for chronic pulmonary obstructive disease from GlaxoSmithKline pPLC and Theravance Inc. which will be launched in the third quarter of 2013 under the brand name Breo Ellipta. It discusses the impact of Breo approval on share price of Theravance based on the research report of analyst Ian Somaiya of Piper Jaffray in May 2013.
ACCESSION #
87593097

 

Related Articles

  • Therapeutics: Strength in numbers. Graham-Rowe, Duncan // Nature;9/27/2012 Supplement, Vol. 489 Issue 7417, pS16 

    The article focuses on various drug developments for treatment of patients with chronic obstructive pulmonary disease (COPD), with patient comliance driving the development of combination therapy. It states that GlaxoSmithKline (GSK) and Theravance Inc. applied for regulatory approval in Europe...

  • GLAXOSMITHKLEIN PLC.  // MondayMorning;3/26/2012, Vol. 20 Issue 13, p1 

    The article presents information on the plans of Glaxosmithkline PLC (GSK) to submit its drug Relovair for regulatory approval in the U.S. and Europe in 2012. It is mentioned that the drug fared better than Advair, GSK's existing lung drug, in only one clinical trial. According to GSK, it will...

  • Panel's Hot Air Ends In Yes for Theravance/GSK COPD Bid. Osborne, Randy // BioWorld Today;9/11/2013, Vol. 24 Issue 174, p1 

    The article reports that members of the Pulmonary Allergy Drugs Advisory Committee of the U.S. Food and Drug Administration have approved the Anoro Ellipta, the inhaler product for the treatment of chronic obstructive pulmonary disorder developed by Theravance Inc. and partner Glaxosmithkline...

  • Anoro Ellipta now available for COPD treatment.  // Caribbean Business;7/3/2014, Vol. 42 Issue 25, p25 

    The article offers information on Anoro Ellipta chronic obstructive pulmonary disease treatment from GlaxoSmithKline and Theravance Inc., which is available in the U.S. and Puerto Rico.

  • FDA ROUNDUP.  // MondayMorning;10/ 1/2012, Vol. 20 Issue 37, p1 

    The article offers information related to U.S. Food and Drug Administration (FDA) drug approval. It states that Bayer AG won approval for a new drug for advanced colon cancer, in which drug to be sold under the brand name Stivarga. It mentions that Theravance Inc. and GlaxoSmithKline PLC said...

  • COPD pipeline grows despite patent cliff. DeArment, Alaric // Drug Store News;2/27/2012, Vol. 34 Issue 3, p42 

    The article reports on the continuous drug development for chronic obstructive pulmonary disease (COPD) despite patient decline. It states that COPD drugs in the third phase of development and drugs that await for the approval of the U.S. Food and Drug Administration (FDA) include Dulera from...

  • Anoro ellipta set to take on U.S. chronic obstructive pulmonary disease market. Powers, Marie // BioWorld Today;12/19/2013, Vol. 24 Issue 243, p1 

    The article reports on the drug approval given by the U.S. Food and Drug Administration (FDA) to Anoro Ellipta, a combination drug for the treatment of chronic obstructive pulmonary disease (COPD), developed by Glaxosmithkline plc (GSK) and partner Theravance Inc., in December 2013. An overview...

  • Panel: Forest, Nycomed COPD Drug Not Ready for Prime Time. Young, Donna // BioWorld Today;4/8/2010, Vol. 21 Issue 67, p1 

    The article reports that the Pulmonary-Allergy Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) did not give approval to Forest Laboratories Inc. and Nycomed GmbH for their drug against chronic obstructive pulmonary disease (COPD) called Daxas. The panel earlier declared...

  • FDA OKs Narrower Indication for Forest Lab's COPD Drug. Powers, Marie // BioWorld Today;3/2/2011, Vol. 22 Issue 41, p1 

    The article reports on the approval granted by the U.S. Food and Drug Administration (FDA) to Forest Laboratories Inc. to market its Daliresp drug in the U.S. which aims to reduce the risk of chronic obstructive pulmonary disease (COPD). Forest has licensed the drug in 2009 from Nycomed GmbH of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics